Literature DB >> 24890836

Novel vaccination strategies against tuberculosis.

Peter Andersen1, Stefan H E Kaufmann2.   

Abstract

The tuberculosis (TB) pandemic continues to rampage despite widespread use of the BCG (Bacillus Calmette-Guérin) vaccine. Novel vaccination strategies are urgently needed to arrest global transmission and prevent the uncontrolled development of multidrug-resistant forms of Mycobacterium tuberculosis. Over the last two decades, considerable progress has been made in the field of vaccine development with numerous innovative preclinical candidates and more than a dozen vaccines in clinical trials. These vaccines are developed either as boosters of the current BCG vaccine or as novel prime vaccines to replace BCG. Given the enormous prevalence of latent TB infection, vaccines that are protective on top of an already established infection remain a high priority and a significant scientific challenge. Here we discuss the current state of TB vaccine research and development, our understanding of the underlying immunology, and the requirements for an efficient TB vaccine.
Copyright © 2014 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24890836      PMCID: PMC4031959          DOI: 10.1101/cshperspect.a018523

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  132 in total

1.  The Achilles heel of BCG.

Authors:  Ian M Orme
Journal:  Tuberculosis (Edinb)       Date:  2010-07-24       Impact factor: 3.131

2.  HIV vaccine failure prompts Merck to halt trial.

Authors: 
Journal:  Nature       Date:  2007-09-27       Impact factor: 49.962

Review 3.  Prospects for better tuberculosis vaccines.

Authors:  H L Collins; S H Kaufmann
Journal:  Lancet Infect Dis       Date:  2001-08       Impact factor: 25.071

4.  Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages.

Authors:  Mario Fabri; Steffen Stenger; Dong-Min Shin; Jae-Min Yuk; Philip T Liu; Susan Realegeno; Hye-Mi Lee; Stephan R Krutzik; Mirjam Schenk; Peter A Sieling; Rosane Teles; Dennis Montoya; Shankar S Iyer; Heiko Bruns; David M Lewinsohn; Bruce W Hollis; Martin Hewison; John S Adams; Andreas Steinmeyer; Ulrich Zügel; Genhong Cheng; Eun-Kyeong Jo; Barry R Bloom; Robert L Modlin
Journal:  Sci Transl Med       Date:  2011-10-12       Impact factor: 17.956

5.  A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Authors:  Sylvie Bertholet; Gregory C Ireton; Diane J Ordway; Hillarie Plessner Windish; Samuel O Pine; Maria Kahn; Tony Phan; Ian M Orme; Thomas S Vedvick; Susan L Baldwin; Rhea N Coler; Steven G Reed
Journal:  Sci Transl Med       Date:  2010-10-13       Impact factor: 17.956

6.  Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis.

Authors:  Andrea Cruz; Alexandra G Fraga; Jeffrey J Fountain; Javier Rangel-Moreno; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Troy D Randall; Jorge Pedrosa; Andrea M Cooper; António G Castro
Journal:  J Exp Med       Date:  2010-07-12       Impact factor: 14.307

7.  Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis.

Authors:  Abebech Demissie; Eliane M S Leyten; Markos Abebe; Liya Wassie; Abraham Aseffa; Getahun Abate; Helen Fletcher; Patrick Owiafe; Philip C Hill; Roger Brookes; Graham Rook; Alimuddin Zumla; Sandra M Arend; Michel Klein; Tom H M Ottenhoff; Peter Andersen; T Mark Doherty
Journal:  Clin Vaccine Immunol       Date:  2006-02

8.  Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis.

Authors:  Xiao-Yan Yang; Qun-Fei Chen; You-Ping Li; Si-Miao Wu
Journal:  PLoS One       Date:  2011-09-06       Impact factor: 3.240

9.  A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells.

Authors:  Arun T Kamath; Anne-Françoise Rochat; Dennis Christensen; Else Marie Agger; Peter Andersen; Paul-Henri Lambert; Claire-Anne Siegrist
Journal:  PLoS One       Date:  2009-06-03       Impact factor: 3.240

10.  Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung.

Authors:  Ankan Gupta; Farhan J Ahmad; Faiz Ahmad; Umesh D Gupta; Mohan Natarajan; Vishwamohan Katoch; Sangeeta Bhaskar
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

View more
  55 in total

1.  Evaluation of a temperature-restricted, mucosal tuberculosis vaccine in guinea pigs.

Authors:  Tuhina Gupta; Monica LaGatta; Shelly Helms; Rebecca L Pavlicek; Simon O Owino; Kaori Sakamoto; Tamas Nagy; Stephen B Harvey; Mark Papania; Stephanie Ledden; Kevin T Schultz; Candace McCombs; Frederick D Quinn; Russell K Karls
Journal:  Tuberculosis (Edinb)       Date:  2018-10-19       Impact factor: 3.131

Review 2.  Tuberculosis and HIV Coinfection.

Authors:  Judith Bruchfeld; Margarida Correia-Neves; Gunilla Källenius
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-26       Impact factor: 6.915

Review 3.  Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis.

Authors:  Jacqueline M Achkar; Rafael Prados-Rosales
Journal:  Curr Opin Immunol       Date:  2018-04-12       Impact factor: 7.486

4.  A multistage mycobacterium tuberculosis subunit vaccine LT70 including latency antigen Rv2626c induces long-term protection against tuberculosis.

Authors:  Xun Liu; Jinxiu Peng; Lina Hu; Yanping Luo; Hongxia Niu; Chunxiang Bai; Qian Wang; Fei Li; Hongjuan Yu; Bingxiang Wang; Huiyu Chen; Ming Guo; Bingdong Zhu
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

Review 5.  The role of B cells and humoral immunity in Mycobacterium tuberculosis infection.

Authors:  John Chan; Simren Mehta; Sushma Bharrhan; Yong Chen; Jacqueline M Achkar; Arturo Casadevall; JoAnne Flynn
Journal:  Semin Immunol       Date:  2014-10-28       Impact factor: 11.130

Review 6.  Tuberculosis vaccine types and timings.

Authors:  Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

7.  Cellular immune response in MDR-TB patients to different protein expression of MDR and susceptible Mycobacterium tuberculosis: Rv0147, a novel MDR-TB biomarker.

Authors:  Alireza Hadizadeh Tasbiti; Shamsi Yari; Seyed Davar Siadat; Payam Tabarsi; Kayvan Saeedfar; Fatemeh Yari
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

8.  Mycobacterial L-forms are found in cord blood: A potential vertical transmission of BCG from vaccinated mothers.

Authors:  Nadya Markova; Georgi Slavchev; Ljubomir Djerov; Asen Nikolov; Tanya Dimova
Journal:  Hum Vaccin Immunother       Date:  2016-06-13       Impact factor: 3.452

9.  Enhancement of Antituberculosis Immunity in a Humanized Model System by a Novel Virus-Vectored Respiratory Mucosal Vaccine.

Authors:  Yushi Yao; Rocky Lai; Sam Afkhami; Siamak Haddadi; Anna Zganiacz; Fatemeh Vahedi; Ali A Ashkar; Charu Kaushic; Mangalakumari Jeyanathan; Zhou Xing
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

10.  Vaccine-mediated immunity to experimental Mycobacterium tuberculosis is not impaired in the absence of Toll-like receptor 9.

Authors:  Archana Gopalakrishnan; Jillian Dietzold; Padmini Salgame
Journal:  Cell Immunol       Date:  2015-12-30       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.